跳至主要内容
临床试验/EUCTR2013-005536-17-ES
EUCTR2013-005536-17-ES进行中(未招募)1 期

Multicenter, randomized and double-blinded clinical trial on the use of antibiotic prophylaxis for EUS guided FNA of pancreatic cystic lesions

Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau ? IIB Sant Pau0 个研究点目标入组 218 人开始时间: 2014年6月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
218

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Patients with a pancreatic cyst requiring EUS-FNA to complete evaluation.
  • - Participant is willing and able to give informed consent for participation in the study.
  • - Age 18 years or older.
  • - Ability to understand study procedures and to comply with them for the entire length of the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 218
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Patients with other co-morbidities requiring antibiotic prophylaxis for endoscopic invasive procedures (such as those with cardiac valve prosthesis).
  • - Cystic lesion of the intestinal wall (foregut or duplication cyst).
  • - Use of antibiotic treatment for any other indication during the 5 days prior to the procedure.
  • - Pregnant woman.
  • - Known allergy/sensitivity to ciprofloxacin.
  • - Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

研究者

发起方
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau ? IIB Sant Pau

相似试验

进行中(未招募)
1 期
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patients
EUCTR2007-001906-26-FRHEXAL Biotech ForschungsGmbH300
进行中(未招募)
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patients
EUCTR2007-001906-26-ATHEXAL AG300
进行中(未招募)
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patients
EUCTR2007-001906-26-BGHEXAL Biotech ForschungsGmbH300
进行中(未招募)
1 期
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsanemia associated with chronic renal insufficiency in predialysis patientsMedDRA version: 9.1Level: LLTClassification code 10058116Term: Nephrogenic anaemia
EUCTR2007-001906-26-SKHEXAL Biotech ForschungsGmbH300
进行中(未招募)
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsanemia associated with chronic renal insufficiency in predialysis patientsMedDRA version: 9.1Level: LLTClassification code 10058116Term: Nephrogenic anaemia
EUCTR2007-001906-26-DEHEXAL AG300